Impact of HLA on the underlying primary diseases in Turkish patients with end-stage renal disease

Renal Failure

Volumn 31, Issue 1, 2009, Pages 44-49

  Karahan, Gonca Emel ^a,c   Seyhun, Yalcin ^a   Oguz, Fatma Savran ^a   Kekik, Cigdem ^a   Onal, Ayse Emel ^a   Yazici, Halil ^b   Turkmen, Aydin ^b   Aydin, Ali Emin ^a   Sever, Mehmet Sukru ^b   Eldegez, Ulug ^a   Carin, Mahmut Nezih ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Disease association; End stage renal disease; HLA; Primary diseases

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B58 ANTIGEN; HLA DR ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HLA SYSTEM; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENE FREQUENCY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINKAGE DISEQUILIBRIUM; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; RISK FACTORS; TURKEY; WAITING LISTS; YOUNG ADULT;

EID: 61649113409     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802546297     Document Type: Article

References (22)

1. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005;16:3736-3741.
2. Turkish Society of Nephrology, Turkish National Registry Reports. National Hemodialysis, Transplantation and Nephrology Registry Report of Turkey, 2006. Available at http://www.tsn.org.tr. Accessed March 2008.
3. Tokgoz B. Renal replacement therapies in chronic renal failure. J Int Med Sci. 2005;21:82-87.
4. Perazella MA, Reilly RF. Chronic kidney disease: A new classification and staging system. Hosp Physician. 2003;45: 18-22.
5. Freedman BI, Espeland MA, Heise ER, Evans J, Canzanello VJ. Racial variation in human leukocyte antigen frequency in insulin dependent diabetic nephropathy. J Am Soc Nephrol. 1993;3:1467-1473.
6. Svejgaard A, Fugger L, Garred P, Madsen HO, Ryder LP. Associations between HLA and disease with notes on additional associations between a 'new' immunogenetic marker and rheumatoid arthritis. In Svejgaard A, Buus S, Fugger L, eds. HLA and disease - the molecular basis. Copenhagen: Munksgaard;1997:301-313.
7. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009-1030.
8. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204:998-1000.
9. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in two hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39:225-235.
10. Eiam-Ong S, Sitprija V. Comorbidities in patients with end stage renal disease in developing countries. Artif Organs. 2002;26:753-756.
11. Middleton D, Williams F, Meenagh A, et al. Analysis of the distribution of HLA-A alleles in populations from five continents. Hum Immunol. 2000;61:1048-1052.
12. Freedman B. End stage renal failure in African Americans: Insights in kidney disease susceptibility. Nephrol Dial Transplant. 2002;17:198-200.
13. Ozdemir FN, Sezer S, Akcay A, Arat Z, et al. Panel reactive antibody positivity and associated HLA antibodies in Turkish renal transplant candidates. Transpl Immunol. 2004;12:185-188.
14. Uyar FA, Dorak MT, Saruhan-Direskeneli G. Human leukocyte antigen-A, -B and -C alleles and human leukocyte antigen haplotypes in Turkey: Relationship to other populations. Tissue Antigens. 2004;64:180-187.
15. Roelen DL, van Bree SPMJ, van Beelen E, Schanz U, van Rood JJ, Claas FHJ. Cytotoxic T lymphocytes against HLA-B antigens are less naive than cytotoxic T lymphocytes against HLA-A antigens. Transplantation. 1994;57:446-450.
16. Svejgaard A, Buus S, Fugger L. Introduction. In Svejgaard A, Buus S, Fugger L, eds. HLA and disease - the molecular basis. Copenhagen: Munksgaard;1997:13-17.
17. Akpolat T, Akpolat I, Karagoz F, Yilmaz E, Kandemir B, Ozen S. Familial Mediterranean fever and glomerulonephritis and review of the literature. Rheumatol Int. 2004;24:43-45.
18. Emiroglu R, Basaran O, Pehlivan S, et al. Effect of amyloidosis on long term survival in kidney transplantation. Transplant Proc. 2005;37:2967-2968.
19. Ozdemir BH, Ozdemir FN, Sezer S, Sar A, Haberal M. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis. Transplant Proc. 2006;38:432-434.
20. Cakar N, Tulek N, Atakan C, Kocak H. The importance of HLA antigens in Turkish patients with familial Mediterranean fever. Hum Immunol. 1996;47:36.
21. Ranningen KS, Bangstad HJ, Undlien DE, Thorsby E. Influence of genetic factors (HLA class II genes, insulin gene region polymorphisms) and metabolic control on the development of diabetic nephropathy. Diabetes Res. 1993;23: 31-40.
22. Gorodezky C, Alaez C, Murguia A, et al. HLA and autoimmune diseases: Type 1 diabetes (T1D) as an example. Autoimmun Rev. 2006;5:187-194.